Ionis Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) develops and commercializes RNA-targeted therapeutics for patients with rare diseases and other unmet medical needs. The company utilizes its proprietary antisense technology platform to design drugs that modulate RNA and protein expression; its marketed products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Waylivra (volanesorsen) for rare cardiovascular and metabolic diseases; and its pipeline encompasses candidates such as pelacarsen for cardiovascular disease, olezarsen for familial chylomicronemia syndrome and familial partial lipodystrophy, and donidalorsen for hereditary angioedema. Ionis operates primarily in the biotechnology sector, targeting pharmaceutical companies through licensing agreements and direct commercialization in select markets, with global operations spanning the United States, Europe, and other regions. Founded in 1989 and headquartered in Carlsbad, California, the company maintains subsidiaries including Akcea Therapeutics, which focuses on commercializing certain antisense medicines prior to its integration into Ionis. In recent developments, Ionis completed the acquisition of certain assets from Novartis in 2024, including rights to pelacarsen; announced positive Phase 3 topline results for olezarsen in severe hypertriglyceridemia in mid-2025; and entered a strategic collaboration with Moderna in late 2024 to develop antisense-based therapies for cardiovascular indications. Additionally, the company reported its Q3 2025 financial results in November 2025, highlighting pipeline advancements and royalty revenues exceeding $200 million from Spinraza, alongside preparations for multiple regulatory filings in 2026.
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?
Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease
Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GSK Targets China's Hepatitis B Market Through New Deal
Tweedy Browne's Strategic Moves: Ionis Pharmaceuticals Inc. Sees Significant Reduction
Ionis to host 2026 virtual Annual Meeting of Stockholders
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis reports first quarter 2026 financial results and highlights progress on key programs
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting